In a report released today, Mark Massaro from Canaccord Genuity maintained a Hold rating on Laboratory Corp (LH), with a price target of $155. The company’s shares opened today at $153.
“We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30.”
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 15.5% and a 56.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Currently, the analyst consensus on Laboratory Corp is a Moderate Buy with an average price target of $181, implying a 18.3% upside from current levels. In a report released today, Deutsche Bank also maintained a Hold rating on the stock with a $155 price target.
See today’s analyst top recommended stocks >>
Based on Laboratory Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $319 million. In comparison, last year the company had a net profit of $181 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Kerrii Anderson, a Director at LH sold 3,700 shares for a total of $604,136.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.